At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
acute lymphoblastic leukemia
late relapse
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
18
12
2019
revised:
02
03
2020
accepted:
05
03
2020
pubmed:
29
3
2020
medline:
17
3
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these 757 (43·2%) relapsed; 691 (91·3%) within three years and 66 (8·7%) beyond. Among these 66 patients, median time to relapse was 47 (37-144) months. Relapse beyond three years occurred in 3·8% of all who achieved CR. The cumulative risk of relapse was 40%, 43% and 45% at three, five and ten years respectively. Out of the 1 752 patients who achieved CR, 11·7% underwent autologous and 40·6% allogeneic transplant, while in CR1. Of the autologous patients, 43·2% relapsed early and 3·4% relapsed late. However, among the allogeneic patients, 13·2% relapsed early and only 1·3% late. The five-year overall survival from relapse was 5·8% and 20% in the early and late relapse patients respectively. In conclusion, late relapse in adults with ALL is not uncommon, and is associated with better outcome after relapse compared to early relapse.
Identifiants
pubmed: 32220069
doi: 10.1111/bjh.16616
pmc: PMC7687130
mid: NIHMS1593966
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-43Subventions
Organisme : NCI NIH HHS
ID : UG1 CA233290
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233234
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189859
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA232760
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180794
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180853
Pays : United States
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Leuk Res. 2014 Aug;38(8):901-6
pubmed: 24986381
Blood. 2007 Feb 1;109(3):944-50
pubmed: 17032921
Leukemia. 2001 Jun;15(6):963-70
pubmed: 11417484
Blood. 2011 Nov 10;118(19):5218-26
pubmed: 21921043
Leukemia. 1998 Oct;12(10):1534-8
pubmed: 9766496
Blood. 2017 Jun 22;129(25):3352-3361
pubmed: 28408464
Haematologica. 2010 Apr;95(4):589-96
pubmed: 20145276
Cancer Genet Cytogenet. 2006 Jul 15;168(2):172-4
pubmed: 16843110
Blood. 1995 Nov 1;86(9):3613-4
pubmed: 7579475
Blood. 2007 Apr 15;109(8):3189-97
pubmed: 17170120
Blood. 2014 Oct 2;124(14):2248-51
pubmed: 25163702
J Clin Oncol. 2011 Apr 20;29(12):1643-9
pubmed: 21357790
Blood. 2017 Nov 9;130(19):2064-2072
pubmed: 28972016
Int J Hematol. 2015 Jan;101(1):52-7
pubmed: 25432437
Blood. 2014 Nov 13;124(20):3059-64
pubmed: 25281606
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4216-21
pubmed: 16537511
Leuk Lymphoma. 2010 May;51(5):778-82
pubmed: 20196624
Med Pediatr Oncol. 1989;17(1):45-7
pubmed: 2913474
Blood. 2005 Dec 1;106(12):3760-7
pubmed: 16105981
Blood. 2012 Sep 6;120(10):2032-41
pubmed: 22493293
J Clin Oncol. 2017 Feb;35(4):394-401
pubmed: 27870571
Blood. 2008 Feb 15;111(4):1827-33
pubmed: 18048644
Br J Haematol. 2015 Jul;170(1):50-5
pubmed: 25823602
Haematologica. 2012 Nov;97(11):1743-50
pubmed: 22580999
Blood. 2003 May 1;101(9):3635-40
pubmed: 12506024
Blood. 2009 Aug 6;114(6):1150-7
pubmed: 19401558
Blood. 2014 Feb 6;123(6):843-50
pubmed: 24277073
Haematologica. 2004 Apr;89(4):427-34
pubmed: 15075076